Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.53 |
| ▸ | RAF1 | P04049 | 12/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972380 | 0.90 | MAP2K1 (0.64) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL960740 | 0.86 | MAP2K1 (0.67) | MAP2K1RAF1 | |
| SCHEMBL959618 | 0.84 | MAP2K1 (0.53) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL961150 | 0.83 | MAP2K1 (0.53) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL974653 | 0.82 | VKORC1 (0.56) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL12694089 | 0.81 | MAP2K1 (0.71) | MAP2K1RAF1 | |
| SCHEMBL959658 | 0.78 | MAP2K1 (0.53) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL973302 | 0.76 | MAP2K1 (0.49) | MAP2K1RAF1KDM4EALDH1A1GLA | |
| SCHEMBL13551752 | 0.75 | MAP2K1 (0.50) | MAP2K1RAF1 | |
| SCHEMBL14325397 | 0.74 | MAP2K1 (0.47) | MAP2K1RAF1KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7026491-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2002008217-A2 | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAP2K1 3709/4885RAF1 623/4885KDM4E 4511/4885 |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885RAF1 699/4885KDM4E 4508/4885 |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885RAF1 699/4885KDM4E 4508/4885 |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAP2K1 3811/4885RAF1 1087/4885KDM4E 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.